Abstract
A wide range of drugs has been associated with the development of acute generalised exanthematous pustulosis (AGEP). Although AGEP is rare and typically self-limiting once the trigger is withdrawn, the reaction can be severe and even fatal in some cases. Prompt diagnosis and appropriate management can aid in minimizing adverse outcomes, and for this, an increased awareness of the triggers and presentation of AGEP would be helpful.
This is a preview of subscription content, log in via an institution to check access.
References
Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP)—a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113–9.
Creadore A, Desai S, Alloo A, et al. Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US. JAMA Dermatol. 2022;158(2):176–83.
Moore MJ, Sathe NC, Ganipisetti VM. Acute generalized exanthematous pustulosis. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2023.
Al Aboud DM, Nessel TA, Hafsi W. Cutaneous adverse drug reaction. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024.
Parisi R, Shah H, Navarini AA, et al. Acute generalized exanthematous pustulosis: clinical features, differential diagnosis, and management. Am J Clin Dermatol. 2023;24(4):557–75.
Vallejo-Yague E, Martinez-De la Torre A, Mohamad OS, et al. Drug triggers and clinic of acute generalized exanthematous pustulosis (AGEP): a literature case series of 297 patients. J Clin Med. 2022;11(2):397.
Stadler P-C, Oschmann A, Kerl-French K, et al. Acute generalized exanthematous pustulosis: clinical characteristics, pathogenesis, and management. Dermatology. 2023;239(3):328–33.
Groot AC. Results of patch testing in acute generalized exanthematous pustulosis (AGEP): a literature review. Contact Dermatitis. 2022;87(2):119–41.
Barbaud A, Castagna J, Soria A. Skin tests in the work-up of cutaneous adverse drug reactions: a review and update. Contact Dermatitis. 2022;86(5):344–56.
Zheng J, Gao Y, Yi X, et al. A case of ceftriaxone-induced acute generalized exanthematous pustulosis/generalized pustular psoriasis overlap. Case Rep Dermatol. 2018;10(1):69–75.
Oh DAQ, Yeo YW, Choo KJL, et al. Acute generalized exanthematous pustulosis: epidemiology, clinical course, and treatment outcomes of patients treated in an Asian academic medical center. JAAD Int. 2021;3:1–6.
Yanes D, Nguyen E, Imadojemu S, et al. Cyclosporine for treatment of acute generalized exanthematous pustulosis: a retrospective analysis. J Am Acad Dermatol. 2020;83.
Zhang L, Xu Q, Lin T, et al. Case report: successful treatment of acute generalized exanthematous pustulosis with secukinumab. Front Med (Lausanne). 2021;8: 758354.
Meiss F, Helmbold P, Meykadeh N, et al. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol. 2007;21(5):717–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and conflict of interest
E. S. Kim, a contracted employee of Adis International Ltd/Springer Nature, and C. Kang, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability
Not applicable.
Rights and permissions
About this article
Cite this article
Kim, E.S., Kang, C. Determine and remove the drug trigger, usually antibiotics, that causes acute generalised exanthematous pustulosis. Drugs Ther Perspect 40, 141–144 (2024). https://doi.org/10.1007/s40267-024-01064-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-024-01064-x